Promises and paradoxes of regulatory T cells in inflammatory bowel disease.

Abstract excerpt

Since their discovery two decades ago, CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) have become the subject of intense investigation by immunologists. Unlike other T cells, which promote an immune response, Tregs actively inhibit inflammation when activated by their cognate antigen, thus raising hope that these cells could be engineered into a highly targeted, antigen-specific, immunosuppressant therapy....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Colitis, Ulcerative
• Share to Crohn Disease
• Share to Forkhead Transcription Factors